Healthcare, Pharma & Life Sciences

Danaher Sets Q3 2026 Earnings Call for October 21

Washington – September 23, 2026 -- Danaher Corporation (NYSE: DHR) will hold its third-quarter 2026 earnings conference call on Wednesday, September 23, 2026, at 8:00 a.m. ET, the company confirmed.

Danaher to webcast hour-long Q3 results discussion on October 21

The call, lasting approximately one hour, will be webcast via the "Investors" section of Danaher's website under "Events & Presentations," alongside a slide presentation. Investors can dial in at 800-267-6316 within the U.S. or +1 203-518-9783 outside the U.S., using Conference ID DHRQ326.

Equifax Launches Automated Credential Verification for Healthcare Hiring

Image
Equifax Launches Automated Credential Verification for Healthcare Hiring

Atlanta – September 23, 2026 -- Equifax has launched Healthcare Report Credential ID, an automated screening tool built to cut delays in verifying healthcare provider licenses and certifications during hiring.

Physician and nursing shortages drive demand for faster onboarding

The U.S. faces a projected shortfall of more than 106,000 physicians and 267,000 registered nurses by 2027, a gap expected to widen over the next decade. Manual credentialing processes currently place administrative strain on hospital staff and delay start dates for patient-facing hires, according to Equifax.

Nutex Health Wins Dual Listing on Nasdaq Texas Starting Sept. 23

Houston – September 23, 2026 -- Nutex Health Inc. (NASDAQ: NUTX) has secured approval to dual-list its common stock on Nasdaq Texas, with trading set to begin on or about Sept. 23, 2026.

Nutex Health keeps primary listing on Nasdaq Global Market while adding Texas venue

The company's shares will continue trading under the ticker "NUTX" on the Nasdaq Global Market. Shares will remain fully fungible across both venues, and the dual listing requires no action from existing stockholders.

Company operates 28 hospital facilities across 12 states under physician-led model

Nutex Health runs a healthcare services and operations business built around a primary care-centric, risk-bearing physician network. The Houston-based firm filed a registration statement on Form 8-A with the U.S. Securities and Exchange Commission under Section 12(b) of the Securities Exchange Act of 1934 in connection with the listing.

Genomma Lab Declares $200 Million Peso Dividend, Its 17th Payout

Mexico City – September 23, 2026 -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) has filed a Notice of Rights with the Bolsa Mexicana de Valores declaring a cash dividend of $0.20 Mexican pesos per common share, totaling $200,000,000.00 pesos based on shares currently outstanding.

Board authorizes 17th dividend under shareholder mandate

The payment marks the company's seventeenth dividend distribution and was approved by Genomma Lab's Board of Directors under powers delegated at the Annual General Shareholders Meeting held on September 23, 2026. The per-share amount is calculated against the total number of LABB shares outstanding on the Mexican Stock Exchange.

AltaPointe Completes $15M BayPointe Expansion, Adds 34 Psychiatric Beds

Image
AltaPointe Completes $15M BayPointe Expansion, Adds 34 Psychiatric Beds

Mobile, Ala. – September 23, 2026 -- AltaPointe Health has completed a $15 million expansion at BayPointe Hospital, adding 34 adult psychiatric beds and raising total capacity from 104 to 138 beds, the organization announced at a ribbon-cutting ceremony held Monday.

Mobile County funded $6 million of the project through American Rescue Plan Act allocations

The Mobile County Commission contributed $6 million in federal pandemic-relief funding toward the $15 million total cost, according to AltaPointe Health. Commission President Connie Hudson and Commissioner Merceria Ludgood attended the ceremony alongside state lawmakers and AltaPointe board members.

MediKarma's AI Health Score Hits 90.6% Correlation With Claims Costs

Image
MediKarma's AI Health Score Hits 90.6% Correlation With Claims Costs

San Ramon, Calif. – September 23, 2026 -- MediKarma, Inc. reported that its proprietary health score achieved a 90.6% correlation with actual claims costs within an 8 million-patient cohort, as the company positions its JackTM and JillTM AI infrastructure as the clinical backbone for direct-to-patient healthcare offerings.

MediKarma's health score correlates at 90.6% with real claims costs across a high-risk patient cohort

The company drew the 8 million-patient cohort from a de-identified population of 65 million patients, selecting individuals based on a minimum claims threshold and membership in the highest-cost disease categories. MediKarma says the correlation demonstrates the value of building patient engagement on an organized, longitudinal clinical picture spanning multiple providers rather than fragmented records.

AAAAI Pushes Penicillin Allergy De-Labeling as 90% of Patients Cleared

Image
AAAAI Pushes Penicillin Allergy De-Labeling as 90% of Patients Cleared

Milwaukee – September 23, 2026 -- More than 90% of patients carrying a documented penicillin allergy in their electronic medical records can safely take the drug after clinical evaluation, according to the American Academy of Allergy, Asthma & Immunology (AAAAI), which is marking National Penicillin Allergy Day on September 28 with a push for wider adoption of allergy "de-labeling" protocols.

Inaccurate allergy labels block access to first-line infection treatment

Penicillin remains the most effective therapy for many bacterial infections, yet patients with unverified allergy labels are routinely steered toward alternative antibiotics. The AAAAI states that removing inaccurate labels through evaluation improves patient outcomes, lowers healthcare costs and supports efforts against antimicrobial resistance.

121G Adds AI Anomaly Monitoring to 10Bridge Healthcare Data Platform

Image
121G Adds AI Anomaly Monitoring to 10Bridge Healthcare Data Platform

Carrollton, Ga. – September 23, 2026 -- 121G has added AI Process Anomaly Monitoring to its 10Bridge data acquisition and interoperability platform, giving healthcare organizations automated detection of irregular file and data processing behavior before it disrupts operations.

New tool flags data deviations before they cause integration failures

The capability continuously monitors jobs processed through 10Bridge, automatically identifying transactions, files, or data that fall outside typical processing patterns. When an anomaly surfaces, the system alerts designated users so they can investigate and resolve issues preemptively, rather than after a failure disrupts downstream systems.

Viva-Thera, XtalPi Nominate HIV Drug Candidate in Seven Months

Image
Viva-Thera, XtalPi Nominate HIV Drug Candidate in Seven Months

Boston – September 22, 2026 -- Viva-Thera has nominated a preclinical candidate targeting the membrane-proximal external region (MPER) of HIV-1 gp41, completing discovery and optimization in seven months through a partnership with AI drug-design firm XtalPi (HKEX: 2228). The biotech, incubated and backed by XtalPi as a strategic shareholder, made its public debut disclosing progress across four HIV modalities: vaccines, long-acting small molecules, gene therapy and cell therapy.

XtalPi's AI screened 10 million compounds to isolate five validated hits

Using generative AI, XtalPi navigated a chemical space of approximately 10 million compounds to identify five hits with strong antiviral activity and favorable drug properties. Continuous optimization of these leads drove the program to preclinical candidate nomination within seven months, according to the companies.